CA2946938C - Modified release coated capsules - Google Patents
Modified release coated capsules Download PDFInfo
- Publication number
- CA2946938C CA2946938C CA2946938A CA2946938A CA2946938C CA 2946938 C CA2946938 C CA 2946938C CA 2946938 A CA2946938 A CA 2946938A CA 2946938 A CA2946938 A CA 2946938A CA 2946938 C CA2946938 C CA 2946938C
- Authority
- CA
- Canada
- Prior art keywords
- capsule
- modified release
- release coating
- capsules
- film forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 202
- 238000000576 coating method Methods 0.000 claims abstract description 120
- 239000011248 coating agent Substances 0.000 claims abstract description 105
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 65
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 21
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 108010010803 Gelatin Proteins 0.000 claims abstract description 16
- 229920000159 gelatin Polymers 0.000 claims abstract description 16
- 239000008273 gelatin Substances 0.000 claims abstract description 16
- 235000019322 gelatine Nutrition 0.000 claims abstract description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 16
- 238000007789 sealing Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 8
- 238000009505 enteric coating Methods 0.000 claims description 23
- 239000002702 enteric coating Substances 0.000 claims description 23
- 229920000642 polymer Polymers 0.000 claims description 19
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000013270 controlled release Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 7
- -1 carboxymethylethyl Chemical group 0.000 claims description 7
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 5
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 5
- 239000008188 pellet Substances 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000008185 minitablet Substances 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 125000005591 trimellitate group Chemical group 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 description 36
- 239000004480 active ingredient Substances 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000011257 shell material Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 14
- 229960004963 mesalazine Drugs 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 8
- 239000007903 gelatin capsule Substances 0.000 description 8
- 238000007654 immersion Methods 0.000 description 8
- 229960002476 metronidazole benzoate Drugs 0.000 description 8
- CUUCCLJJOWSASK-UHFFFAOYSA-N metronidazole benzoate Chemical compound CC1=NC=C([N+]([O-])=O)N1CCOC(=O)C1=CC=CC=C1 CUUCCLJJOWSASK-UHFFFAOYSA-N 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 4
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 4
- 229960000907 methylthioninium chloride Drugs 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 229920003154 Eudragit® NM polymer Polymers 0.000 description 1
- 229920003156 Eudragit® RL PO Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14168871.3A EP2946773A1 (en) | 2014-05-19 | 2014-05-19 | Modified release coated capsules |
| EP14168871.3 | 2014-05-19 | ||
| PCT/EP2015/060638 WO2015177028A1 (en) | 2014-05-19 | 2015-05-13 | Modified release coated capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2946938A1 CA2946938A1 (en) | 2015-11-26 |
| CA2946938C true CA2946938C (en) | 2022-07-12 |
Family
ID=50732832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2946938A Active CA2946938C (en) | 2014-05-19 | 2015-05-13 | Modified release coated capsules |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11160762B2 (enExample) |
| EP (2) | EP2946773A1 (enExample) |
| JP (2) | JP2017515879A (enExample) |
| CN (1) | CN106456554B (enExample) |
| AU (1) | AU2015263311B2 (enExample) |
| CA (1) | CA2946938C (enExample) |
| DK (1) | DK3145497T3 (enExample) |
| ES (1) | ES2832699T3 (enExample) |
| HK (1) | HK1215385A1 (enExample) |
| NZ (1) | NZ725577A (enExample) |
| SI (1) | SI3145497T1 (enExample) |
| WO (1) | WO2015177028A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7650660B2 (ja) | 2017-11-17 | 2025-03-25 | エボニック オペレーションズ ゲーエムベーハー | コーティングされた硬カプセルを製造する方法 |
| CN109330988A (zh) * | 2018-11-14 | 2019-02-15 | 广西达庆生物科技有限公司 | 一种含有抗菌药物的药敏胶囊及其制备方法 |
| CA3137514A1 (en) | 2019-05-15 | 2020-11-19 | Vinay JAIN | Process for preparing filled hard-shell capsules with (meth)acrylate copolymer based coatings with a capsule-filling machine |
| EP3968967B1 (en) | 2019-05-15 | 2025-11-26 | Evonik Operations GmbH | Process for preparing filled hard-shell capsules with cellulose or starch-based coatings with a capsule-filling machine |
| CN111388454A (zh) * | 2020-04-05 | 2020-07-10 | 刘立新 | 一种消化道定时崩解胶囊及其生产工艺 |
| GB202006074D0 (en) * | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| CN112472715B (zh) * | 2020-12-18 | 2023-06-23 | 华熙生物科技股份有限公司 | 一种碳酸氢钠肠溶胶囊及其制备方法 |
| CN117241788A (zh) | 2021-04-20 | 2023-12-15 | 江苏恒瑞医药股份有限公司 | 用于药物特定递送的胶囊及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6229515A (ja) | 1985-07-30 | 1987-02-07 | Shinjiro Tsuji | 硬カプセル剤のフイルムコ−テイング方法 |
| WO2003013480A1 (en) * | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
| US20030124196A1 (en) * | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| US8168170B2 (en) * | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| EP2243487A1 (en) | 2009-04-23 | 2010-10-27 | Actogenix N.V. | Enteric coated formulation |
| AU2012322323B2 (en) * | 2011-10-11 | 2016-04-21 | Sun Pharmaceutical Industries Limited | A gastroretentive dosage system and process of preparation thereof |
| JP6062802B2 (ja) | 2012-08-23 | 2017-01-18 | 日清ファルマ株式会社 | キトサン含有組成物及びキトサンコーティング組成物 |
| EP2968187A4 (en) | 2013-03-14 | 2016-08-17 | Therabiome Llc | TARGETED GASTROINTESTINAL RELEASE OF PROBIOTIC ORGANISMS AND / OR THERAPEUTICS |
-
2014
- 2014-05-19 EP EP14168871.3A patent/EP2946773A1/en not_active Withdrawn
-
2015
- 2015-05-13 US US15/312,632 patent/US11160762B2/en active Active
- 2015-05-13 EP EP15723690.2A patent/EP3145497B1/en active Active
- 2015-05-13 CA CA2946938A patent/CA2946938C/en active Active
- 2015-05-13 DK DK15723690.2T patent/DK3145497T3/da active
- 2015-05-13 AU AU2015263311A patent/AU2015263311B2/en active Active
- 2015-05-13 WO PCT/EP2015/060638 patent/WO2015177028A1/en not_active Ceased
- 2015-05-13 CN CN201580025649.1A patent/CN106456554B/zh active Active
- 2015-05-13 SI SI201531454T patent/SI3145497T1/sl unknown
- 2015-05-13 NZ NZ725577A patent/NZ725577A/en unknown
- 2015-05-13 JP JP2016568632A patent/JP2017515879A/ja active Pending
- 2015-05-13 ES ES15723690T patent/ES2832699T3/es active Active
-
2016
- 2016-03-23 HK HK16103369.9A patent/HK1215385A1/en unknown
-
2019
- 2019-12-23 JP JP2019231023A patent/JP7041333B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215385A1 (en) | 2016-08-26 |
| CN106456554A (zh) | 2017-02-22 |
| AU2015263311B2 (en) | 2020-01-16 |
| CA2946938A1 (en) | 2015-11-26 |
| AU2015263311A1 (en) | 2016-11-10 |
| JP2017515879A (ja) | 2017-06-15 |
| EP3145497B1 (en) | 2020-10-28 |
| NZ725577A (en) | 2023-06-30 |
| EP3145497A1 (en) | 2017-03-29 |
| US11160762B2 (en) | 2021-11-02 |
| JP7041333B2 (ja) | 2022-03-24 |
| DK3145497T3 (da) | 2020-11-09 |
| WO2015177028A1 (en) | 2015-11-26 |
| JP2020063290A (ja) | 2020-04-23 |
| ES2832699T3 (es) | 2021-06-11 |
| SI3145497T1 (sl) | 2021-01-29 |
| US20170079927A1 (en) | 2017-03-23 |
| CN106456554B (zh) | 2021-03-09 |
| EP2946773A1 (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11998641B2 (en) | Modified release coated capsules | |
| CA2946938C (en) | Modified release coated capsules | |
| EP0827398B1 (en) | Pharmaceutical dosage form for colonic delivery | |
| CN107174572B (zh) | 用于结肠特异性递送的药物组合物 | |
| CA2617051C (en) | Ph-controlled pulsatile delivery system, methods for preparation and use thereof | |
| WO2019245975A1 (en) | Compositions for delivery of reboxetine | |
| HK1230515B (en) | Modified release coated capsules | |
| HK40078378A (en) | Modified release coated capsules | |
| WO2017156214A1 (en) | Pharmaceutical compositions for colon-specific delivery | |
| KR20250164363A (ko) | 부티르산의 장 표적화된 전달을 위한 제형 및 이의 제조 방법 | |
| JP2014139210A (ja) | ｐＨ制御パルス送達システム、その調製法及び使用法 | |
| NZ565272A (en) | pH-controlled pulsatile delivery system, methods for preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200415 |
|
| EEER | Examination request |
Effective date: 20200415 |
|
| EEER | Examination request |
Effective date: 20200415 |